retatrutide hfpef trial Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished RAPID-HF Trial

T helper type 17 immune response plays an indispensable role for development of iodine-induced autoimmune thyroiditis in nonobese diabetic-H2h4 mice

Non-human primates would be more accurate animal model due to their greater anatomical and physiological resemblance to humans

Even then, patients need to understand that compounded drugs are not FDA approved, as they have not undergone rigorous trials for safety and effectiveness

This is all well in good, but amphetamines stimulate the adrenal glands to produce more and more cortisol over the long term

Ozempic is a diabetes medication that is often used off-label for weight loss

Endothelial expression of fractalkine (CX3CL1) is induced by Toll-like receptor 3 signaling in cultured human glomerular endothelial cells